Plymouth Meeting, PA – According to filings with the U.S. Securities and Exchange Commission, GENEOS Therapeutics is raising $11,999,995.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Niranjan Sardesai played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About GENEOS Therapeutics

At Geneos, our passion is to develop Exquisitely Personalized Immunotherapies to unleash the most powerful force against Cancer û your body’s own immune system. We have established our GT-EPICTM Platform to drive development of individualized treatments. Our approach is to target unique neoantigens (abnormal mutations and genomic variations produced by cancer cells) from individual patient tumors to develop novel treatments for cancer. Our technology is designed to identify relevant neoantigen targets and then design, manufacture, and deliver tumor- specific neoantigen-targeted personalized immunotherapies.

To learn more about GENEOS Therapeutics, visit http://geneostx.com/

Contact:
Niranjan Sardesai, President and Chief Executive Officer
267-440-4232
https://www.linkedin.com/in/niranjan-sardesai-7645131/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved